Might treatment outcomes be improved by considering the heterogeneity of primary brain tumours and tumour-associated microglial populations?


Microglia are the resident innate immune cells of the immune-privileged CNS and, as such, represent the first line of defence against tissue injury and infection. Given their location, microglia are undoubtedly the first immune cells to encounter a developing primary brain tumour.